Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 19 (1), 150-5

Long-term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients With De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study

Affiliations
Clinical Trial

Long-term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients With De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study

Aline Tanguy-Schmidt et al. Biol Blood Marrow Transplant.

Abstract

We report here the results of the GRAAPH-2003 trial with long-term follow-up in 45 patients with de novo Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). Imatinib-based strategy improved the 4-year overall survival (OS) up to 52% versus 20% in the pre-imatinib LALA-94 trial (P = .0001). Despite the selection in patients who actually underwent transplantation, these results suggest that allogeneic or autologous stem cell transplants (SCTs) still have a place in overcoming the poor prognosis of Ph+ ALL in the era of imatinib therapy. OS was 50% after allogeneic SCT (24 patients), 33% in patients without a transplantation (9 patients), and 80% after autologous SCT (10 patients without allogeneic donor or >55 years, including 7 patients in complete molecular response).

Similar articles

See all similar articles

Cited by 26 articles

See all "Cited by" articles

Publication types

MeSH terms

LinkOut - more resources

Feedback